Comparison between Avalon Technologies IPO and Mankind Pharma IPO.
Avalon Technologies IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Mankind Pharma IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Avalon Technologies IPO is up to ₹865.00 Cr whereas the issue size of the Mankind Pharma IPO is up to ₹4,326.36 Cr. The final issue price of Avalon Technologies IPO is ₹436.00 per share and of Mankind Pharma IPO is ₹1,080.00 per share.
| Avalon Technologies IPO | Mankind Pharma IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹1 per share |
| Issue Price (Lower) | ₹415.00 per share | ₹1,026.00 per share |
| Issue Price (Upper) | ₹436.00 per share | ₹1,080.00 per share |
| Issue Price (Final) | ₹436.00 per share | ₹1,080.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 34 shares | 13 shares |
| Fresh Issue Size | 73,39,449 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹320.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 1,24,99,997 shares | 4,00,58,844 shares |
| OFS Issue Size (Amount) | up to ₹545.00 Cr | up to ₹4,326.36 Cr |
| Issue Size Total | 1,98,39,446 shares | 4,00,58,844 shares |
| Issue Size Total (Amount) | up to ₹865.00 Cr | up to ₹4,326.36 Cr |
Avalon Technologies IPO opens on Apr 03, 2023, while Mankind Pharma IPO opens on Apr 25, 2023. The closing date of Avalon Technologies IPO and Mankind Pharma IPO is Apr 06, 2023, and Apr 27, 2023, respectively.
| Avalon Technologies IPO | Mankind Pharma IPO | |
|---|---|---|
| Anchor Bid Date | Mar 31, 2023 | Apr 24, 2023 |
| Issue Open | Apr 03, 2023 | Apr 25, 2023 |
| Issue Close | Apr 06, 2023 | Apr 27, 2023 |
| Basis Of Allotment (Tentative) | Apr 12, 2023 | May 03, 2023 |
| Initiation of Refunds (Tentative) | Apr 13, 2023 | May 04, 2023 |
| Credit of Share (Tentative) | Apr 17, 2023 | May 05, 2023 |
| Listing date (Tentative) | Apr 18, 2023 | May 09, 2023 |
| Anchor Lockin End date 1 | May 12, 2023 | Jun 02, 2023 |
| Anchor Lockin End date 2 | Jul 11, 2023 | Aug 01, 2023 |
Avalon Technologies IPO P/E ratio is 55.54, as compared to Mankind Pharma IPO P/E ratio of 32.5.
| Avalon Technologies IPO | Mankind Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 70.75 | 79.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 51.24 | 76.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 55.54 | 32.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹2846.76 Cr. | ₹43263.60 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 85.9 | 27.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.4 | 26.10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 3.64 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹11.30 | ₹33.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 85.86 | 27.70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avalon Technologies IPO Retail Individual Investors (RII) are offered 19,83,944 shares while in Mankind Pharma IPO retail investors are offered 19,83,944 shares. Qualified Institutional Buyers (QIB) are offered 59,51,835 shares in Avalon Technologies IPO and 80,11,769 shares in Mankind Pharma IPO.
| Avalon Technologies IPO | Mankind Pharma IPO | |
|---|---|---|
| Anchor Investor Reservation | 89,27,751 shares | 1,20,17,652 shares |
| Market Maker Reservation | ||
| QIB | 59,51,835 shares | 80,11,769 shares |
| NII | 29,75,916 shares | 60,08,827 shares |
| RII | 19,83,944 shares | 1,40,20,596 shares |
| Employee | ||
| Others | ||
| Total | 1,98,39,446 shares | 4,00,58,844 shares |
Avalon Technologies IPO subscribed 2.34x in total, whereas Mankind Pharma IPO subscribed 15.32x.
| Avalon Technologies IPO | Mankind Pharma IPO | |
|---|---|---|
| QIB (times) | 3.77x | 49.16x |
| NII (times) | 0.43x | 3.80x |
| Big NII (times) | 0.44x | 4.99x |
| Small NII (times) | 0.41x | 1.41x |
| RII (times) | 0.88x | 0.92x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 2.34x | 15.32x |
